Document is current
Any future updates will be listed below
-
Authors
Fowler, Douglas M. http://orcid.org/0000-0001-7614-1713
Adams, David J. http://orcid.org/0000-0001-9490-0306
Gloyn, Anna L. http://orcid.org/0000-0003-1205-1844
Hahn, William C.
Marks, Debora S. http://orcid.org/0000-0001-9388-2281
Muffley, Lara A. http://orcid.org/0000-0002-3035-3339
Neal, James T. http://orcid.org/0000-0002-3962-8570
Roth, Frederick P. http://orcid.org/0000-0002-6628-649X
Rubin, Alan F. http://orcid.org/0000-0003-1474-605X
Starita, Lea M. http://orcid.org/0000-0003-2870-5099
Hurles, Matthew E. http://orcid.org/0000-0002-2333-7015
-
Funding
Funding for this research was provided by:
NHGRI (HG011989, HG011969, HG010461)
NHLBI Division of Intramural Research (HL164675)
NIDDK (UM-1DK126185)
NIH (U01CA176058, 1DP2GM146252, 1R01CA260415)
NovoNordisk (NNF21SA0072102)
Cancer Research UK (CG-MAVE: EDDPGM-Nov22/100004)
Chan Zuckerberg Initiative (CZI2018- 191853)
- License Information
-
More Information
Article History
Received: 2 June 2023
Accepted: 13 June 2023
First Online: 3 July 2023
Declarations
:
: Not applicable.
: A.L.G. declares that her spouse is an employee of Genentech and holds stock options in Roche. D.J.A. is a consultant for Microbiotica and Astra Zeneca. D.S.M. is a consultant for Insitro, Dyno and Octant. J.T.N. receives research support from Bristol Myers Squibb. F.P.R. holds shares in Ranomics, Inc., and is an investor and advisor for SeqWell, Inc. and Constantiam Biosciences, Inc. L.M.S. is a consultant for Nostos Genomics. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, MPM Capital, Tyra Biosciences, Frontier Medicines, Jubilant Therapeutics, KSQ Therapeutics, RAPPTA Therapeutics, Serinus Biosciences, Hexagon Bio, Function Oncolog, Riva Therapeutics, and Calyx. M.E.H. is a consultant for AstraZeneca and co-founder, director, shareholder of Congenica Ltd.
